The ALS/MND prevalence in Sweden estimated by riluzole sales statistics.
OBJECTIVE
To determine whether sales statistics for riluzole can be used as a marker for the prevalence of amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) in Sweden.


METHODS
A questionnaire was sent to all neurological units in Sweden asking about the numbers of patients with ALS/MND and whether these patients were treated with riluzole. Sales statistics for riluzole were obtained from the 906 public pharmacies and 89 hospital pharmacies in Sweden.


RESULTS
Eighty percent of the neurological units answered the questionnaire. The estimated prevalence in September 2003 from the questionnaire was 5.4/100,000 inhabitants. The sales expressed in defined daily dose/100,000 inhabitants/day was 3.8. For the counties the correlation between these two parameters was 0.83.


CONCLUSIONS
Estimated prevalence is highly correlated with sales statistics for riluzole. Riluzole sales statistics could be used as a crude marker for the prevalence of ALS/MND in Sweden.
Nygren
I
I
Department of Neuroscience, Neurology, Uppsala University Hospital, Uppsala, Sweden. ingela.nygren@neurologi.uu.se
Antonova
K
K
Mattsson
P
P
Askmark
H
H
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000453:epidemiology*; D003132:Commerce / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000600:supply & distribution* / Q000627:therapeutic use; D010594:Pharmacies / Q000706:statistics & numerical data; D015995:Prevalence; D019782:Riluzole / Q000600:supply & distribution* / Q000627:therapeutic use; D013548:Sweden / Q000453:epidemiology
D018696:Neuroprotective Agents; D019782:Riluzole